Allemani C,Weir HK,Helena Carreira HK .2015 .Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet, 385(9972) : 977-1010.
Anastasiadou E,Messina E,Sanavia T .2021 .MiR200c-3p contrasts PD-L1 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of β-catenin and c-myc. Cells, 10(3) : 519.
Bekos C,Pils D,Dekan S D .2021 .PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. Sci. Rep, 11(1) : 6400.
Bygdeman M,Swahn M L,Gemzell-Danielsson K .1993 .Mode of action of RU 486. , 25(1) : 61-64.
De Angelis R,Sant M,Coleman MP M .2014 .Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5 a population-based study. Lancet Oncol., 15(1) : 23-34.
Dochez V,Caillon H,Vaucel E,Dimet J,Winer N J .2019 .Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J. Ovarian Res., 12(1) : 28.
Du SY,Huang XX,Li NM .2020 .MiR-127-3p inhibits proliferation of ovarian cancer in rats through down-regulating MAPK4. Eur. Rev. Med, : 10383-10390.
Filippova N,Yang X,An Z X .2018 .Blocking PD1/PDL1 interactions together with MLN4924 therapy is a potential strategy for glioma treatment. Cancer Sci. Ther, 10(8) : 190-197.
Goyeneche AA,Caron RW,Telleria CM .2007 .Mifepristone inhibits ovarian cancer cell growth in vitro. Clin. Cancer Res., 13(11) : 3370-3379.
Guo H,Ha CF,Dong H,Yang ZJ,Ma Y,Ding YH Y .2019 .Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cancer Cell Int. , 19(12) : 2451-2460.
Kim O,Park EY,Kwon SY .2020 .Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl. Acad. Sci., 117(50) : 31993-32004.
Kou X,Ding H,Li L .2021 .Hsa-miR-105-1 regulates cisplatin-resistance in ovarian carcinoma cells by targeting ANXA9. Anal. Cell Pathol, : 1-11.
Krzystyniak J,Ceppi L,Dizon DS,Birrer MJ DS .2016 .Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Annals of oncology, 27(1) : i4-i10.
Kythreotou A,Siddique A,Mauri FA .2018 .PD-L1. Clin Pathol, 71(3) : 189-194.
La Vecchia C .2017 .Ovarian cancer: Epidemiology and risk factors. Eur. J. Cancer Prev, 26(1) : 55-62.
Lin WM,Ye HY,You KL,Chen L KL .2020 .Upregulation of circ LARP4 suppresses cell proliferation and migration in ovarian cancer by regulating miR513b-5p/LARP4 axis. Cancer Cell Int, 20(39) : i58-i62.
Li N,Zhan X Q .2020 .Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNAEIF4A3-mRNA axes. EPMA Journal, : 1-21.
Li Q,Jiang CW,Wang Y,Wei MH,Zheng HJ,Xu YQ,Xu XG,Jia FY,Liu K,Sun G,Zang JH,Mo P .2019 .Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating PIM1. Naunyn Schmiedebergs Arch. , 392(12) : 1477-1489.
Liu R,Chen HJ,Zhao P,Chen CH,Liang HC,Yang CY,Zhou ZM,Zhi X,Liu SL,Chen CS .2020 .003 suppresses triplenegative breast cancer cell growth partially via miR153-KLF5 axis. Int. J. Biol. Sci., 16(4) : 611-619.
Liu R,Shi P,Nie Z,Liang H,Zhou Z,Chen W,Chen H,Dong C,Yang R,Liu S,Chen C .2016 .Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression. Theranostics, 6(4) : 533-544.
Llosa NJ,Cruise M,Tam A .2015 .The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov, 5(1) : 43-51.
Momenimovahed Z,Tiznobaik A,Taheri S,Salehiniya H S .2019 .Ovarian cancer in the world: Epidemiology and risk factors. Int. J. Womens Health, 11 : 287-299.
Oliveira AF,Bretes L,Furtado I .2019 .Review of PD-1/PD-L1 inhibitors in metastatic DMMR/MSI-H colorectal cancer. Front Oncol., 14(9) : 396.
Ponandai‐Srinivasan S,Lalitkumar PG,Garcia L,Varghese SJ,Carlson JW,Gemzell-Danielsson K,Radestad AF K .2019 .Mifepristone mediates antiproliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA (1-/2-) carriers. , 98(2) : 250-261.
Singh A,Gupta S,Sachan M .2019 .Epigenetic biomarkers in the management of ovarian cancer: current prospectives. Front Cell Dev, 7 : 1-35.
Sun D,Liu J,Zhou L J .2019 .Upregulation of circular RNA circ‑FAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR‑646/VAMP2. Oncol. Rep, 42(6) : 2728-2737.
Vegeto E,Allan GF,Schrader WT,Tsai MJ,McDonnell DP,O'Malley BW DP .1992 .The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell, 69(4) : 703-713.
Wang YN,Bao W,Liu Y,Wang SY,Xu SJ,Li X,Li YL,Wu SF .2018 .-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death & Disease, 9(5) : 69-90.
Wu AY,Gu LY,Cang W,Cheng MX,Wang WJ,Di W,Huang L,Qiu LH .2019 .Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation. Bio Med Central, 38(1) : 176.
Yun JC,Jo KH,Sang HH .2021 .Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer. Ann. Nucl. Med, 35(4) : 415-420.
Zhang C,Liu W,Li F .2021 .Hsa_circ_0015326 promotes the proliferation, invasion and migration of ovarian cancer through. miR-127-3p/MYB. Cancer Manag. Res., 13 : 2265-2277.
Zhang L,Hapon MB,Goyeneche AA,Srinivasan R,Gamarra-Luques CD,Callegari EA,Drappeau DD,Terpstra EJ,Pan B,Knapp JR,Chien J,Wang XJ,Eyster KM,Telleria CM .2016 .Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasomeor lysosome inhibitors. Mol Oncol, 10(7) : 109-117.
Zhang X,Hou GX,Liu AD,Xu H,Guan Y,Wu YS,Deng J,Cao X .2019 .Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways. Cell Death Dis, 10(10) : 9-29.